GLP-1s (glucagon-like peptide-1 receptor agonists), like Wegovy, Ozempic, or generic liraglutide, have helped you reach your ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

The research suggests that liraglutide, a drug originally developed for diabetes (Victoza) and weight management (Saxenda), may significantly reduce the frequency of debilitating migraine.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Liraglutide has been previously shown to increase bone formation and prevent bone loss in obese women who have lost weight.. For this new study, 195 obese participants shed at least 5% of their ...

Abstract. Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated ...

Big Number. 650 million. That’s how many adults worldwide are obese, more than triple the number in 1975, and around 1.3 billion are overweight, according to WHO. Over 340 million children ...

In a randomized trial of 2.4-mg semaglutide, 3.0-mg liraglutide, and matching placebo for both, those on semaglutide plus diet and exercise saw a 9.4% greater average loss in baseline weight ...

However, liraglutide trended towards fewer events versus the other three agents. Liraglutide was significantly better than sitagliptin when it came to the development of any CV disease.

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got a placebo, according to a new study. CNN values your feedback 1.